Silymarin modified polysulfone hollow fiber membranes with antioxidant, anti‐M1 macrophage polarization and hemocompatibility for blood purification
Journal of Biomedical Materials Research Part B: Applied Biomaterials · 2023-10 · 111 (10) · 1785-1799
DOI: 10.1002/jbm.b.35285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biomedical Materials Research Part B: Applied Biomaterials, online erschienen am 31.05.2023. Verfasst von Peichen Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Separation Membranes and Membrane Processes, National Center for International Joint Research on Separation Membranes, School…. Hauptthemen laut MEDLINE: Antioxidants, Silymarin. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Tianjin City, Natural Science Foundation of Tianjin Municipal Science and Technology Commission.
Abstract (Originalsprache)
Oxidative stress is highly prevalent in maintenance hemodialysis patients and increases the risk of cardiovascular morbidity and mortality. Silymarin (SM) is a natural compound extracted from plants, and has been shown to have pharmacological effects such as antioxidant, anti‐inflammatory, cytoprotective, and anti‐nephrotoxicity. SM‐modified polysulfone (PSF) hemodialysis membranes were prepared by an immersion‐precipitation phase transition method. The experimental results showed that the modified membranes effectively scavenged free radicals, significantly inhibited lipid peroxidation, and had good antioxidant stability (60 days). The PSF/SM antioxidant membranes (H‐3) had no pro‐inflammatory effect, which was confirmed by the result of anti‐M1 macrophage polarization. Furthermore, the hemolysis rate (2%), blood cell deformation (3.7%), and inhibition of erythrocyte and platelet adhesion were improved by the SM‐modified PSF membranes. All the results suggest that PSF/SM blended hollow fiber membranes are promising for application in hemodialysis membranes to improve oxidative stress status and reduce inflammation and complications in patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Separation Membranes and Membrane Processes, National Center for International Joint Research on Separation Membranes, School of Materials Science and Engineering, Tiangong University, Tianjin, C…
- Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, Nankai University Affiliated Third Centre Hospital, Tianjin, China.
ORCID-Profile: Ning Yang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Tianjin City
- Natural Science Foundation of Tianjin Municipal Science and Technology Commission
Zitieren
APA
Wang, P., Yang, N., Luo, Y., Wang, G., Zhou, S., Huang, S., Chen, L., & Zhao, Y. (2023). Silymarin modified polysulfone hollow fiber membranes with antioxidant, anti‐M1 macrophage polarization and hemocompatibility for blood purification. Journal of Biomedical Materials Research Part B: Applied Biomaterials, 111(10), 1785-1799. https://doi.org/10.1002/jbm.b.35285
Vancouver
Wang P, Yang N, Luo Y, Wang G, Zhou S, Huang S, et al. Silymarin modified polysulfone hollow fiber membranes with antioxidant, anti‐M1 macrophage polarization and hemocompatibility for blood purification. Journal of Biomedical Materials Research Part B: Applied Biomaterials. 2023;111(10):1785-1799. doi:10.1002/jbm.b.35285
BibTeX
@article{Wang2023,
author = {Wang, Peichen and Yang, Ning and Luo, Ying and Wang, Gan and Zhou, Shuaizhen and Huang, Shuai and Chen, Li and Zhao, Yiping},
title = {Silymarin modified polysulfone hollow fiber membranes with antioxidant, anti‐M1 macrophage polarization and hemocompatibility for blood purification},
journal = {Journal of Biomedical Materials Research Part B: Applied Biomaterials},
year = {2023},
volume = {111},
number = {10},
pages = {1785--1799},
doi = {10.1002/jbm.b.35285}
}
EUVIMED